These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10555509)

  • 1. Outpatient treatment of thyroid cancer using high doses of iodine 131.
    Caldwell CB; Ehrlich LE
    Can Assoc Radiol J; 1999 Oct; 50(5):331-6. PubMed ID: 10555509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient
    Gomes-Lima CJ; Wu D; Kharazi PH; Khojekar GJ; Ringel MD; Vetter RJ; Bloom G; Burman KD; Wartofsky L; Van Nostrand D
    Thyroid; 2017 Dec; 27(12):1558-1565. PubMed ID: 29132255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma.
    Grigsby PW; Siegel BA; Baker S; Eichling JO
    JAMA; 2000 May; 283(17):2272-4. PubMed ID: 10807387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated dose rates to members of the public from external exposure to patients with 131I thyroid treatment.
    Dewji S; Bellamy M; Hertel N; Leggett R; Sherbini S; Saba M; Eckerman K
    Med Phys; 2015 Apr; 42(4):1851-7. PubMed ID: 25832075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.
    Willegaignon J; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
    Clin Nucl Med; 2011 Jun; 36(6):440-5. PubMed ID: 21552020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
    Parthasarathy KL; Crawford ES
    J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
    Al-Haj AN; Lagarde CS; Lobriguito AM
    Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioprotection using iodine-131 for thyroid cancer and hyperthyroidism: a review.
    Al-Shakhrah IA
    Clin J Oncol Nurs; 2008 Dec; 12(6):905-12. PubMed ID: 19064384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid remnant ablation with 1110MBq of 131I in outpatients: measurement of effective dose to household members and establishment of safety precautions.
    Yoshimura M; Tsutsui H; Ikeda N; Koizumi K
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):101-8. PubMed ID: 23474638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioactivity of blood samples taken from thyroidectomized thyroid carcinoma patients after therapy with (131)I.
    Larkin A; Millan E; Noz M; Wagner S; Friedman K; Blum M
    Thyroid; 2011 Sep; 21(9):1009-12. PubMed ID: 21834682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital discharge of patients with thyroid carcinoma treated with 131I.
    Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
    J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-day iodine kinetics is useful for individualizing radiation safety precautions for thyroid carcinoma patients.
    Tenhunen M; Lehtonen S; Heikkonen J; Halonen P; Mäenpää H
    Nucl Med Commun; 2013 Dec; 34(12):1208-15. PubMed ID: 24077636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation doses to patient's relatives following radioiodine therapy.
    Sulaiman BT; Clarke SE
    Med J Malaysia; 1996 Mar; 51(1):131-3. PubMed ID: 10967992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of patients after therapy with unsealed radionuclides.
    International Commission on Radiological Protection
    Ann ICRP; 2004; 34(2):v-vi, 1-79. PubMed ID: 15571759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
    Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
    Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient therapeutic 131I for thyroid cancer.
    Panzegrau B; Gordon L; Goudy GH
    J Nucl Med Technol; 2005 Mar; 33(1):28-30. PubMed ID: 15731017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVALUATION OF THE RELEASE CRITERIA FROM HOSPITAL OF THYROID CARCINOMA PATIENT TREATED WITH 131I.
    Lahfi Y; Anjak O
    Radiat Prot Dosimetry; 2016 Dec; 171(4):534-538. PubMed ID: 26590393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.